Immunotherapy of bladder cancer targeting p53

Journal of Urology

Volumn 162, Issue 5, 1999, Pages 1806-1811

  Peralta, Elizabeth A ^a   Liu, Xiping ^a   Mccarty, Todd M ^a   Wilson, Timothy G ^a   Diamond, Don J ^a   Ellenhorn, Joshua D I ^a  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

Author keywords

Adoptive immunotherapy; Bladder carcinoma; Cytotoxic T lymphocytes; p53

Indexed keywords

PROTEIN P53;

ADOPTIVE IMMUNOTHERAPY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CANCER; BLADDER CARCINOMA; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; HUMAN; IMMUNOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; XENOGRAFT;

EID: 0032883886     PISSN: 00225347     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0022-5347(05)68242-0     Document Type: Article

References (38)

1. Landis, S. H., Murray, T., Bolden, S. and Wingo, P. A.: Cancer statistics, 1998. CA: Cancer J. Clin., 48: 6, 1998.
2. Koch, M. O. and Smith, J. A. Jr.: Management of superficial bladder cancer Ta/T1/TIS. In: Comprehensive Textbook of Genitourinary Oncology. Edited by N. J. Vogelzang, P. T. Scardino, W. U. Shipley and D. S. Coffey. Baltimore: Williams & Wilkins, p. 405, 1996.
3. Ovesen, H., Horn, T. and Steven, K.: Long-term efficacy of intravesical bacillus calmette-guerin for carcinoma in situ: relationship of progression to histological response and p53 nuclear accumulation. J. Urol., 157: 1655, 1997.
4. Hudson, M. A., Gerber, A. J. and Ratliff, T. L.: Management of superficial bladder cancer Ta/T1/TIS. In: Comprehensive Textbook of Genitourinary Oncology. Edited by N. J. Vogelzang, P. T. Scardino, W. U. Shipley and D. S. Coffey. Baltimore: Williams & Wilkins, p. 427, 1996.
5. Ratliff, T., Gillen, D. and Catalona, W. J.: Requirement of a thymus dependent immune response for BCG-mediated antitumor activity. J. Urol., 137: 155, 1986.
6. Kaempfer, R., Gerez, L. and Farbstein, H.: Prediction of response to treatment in superficial bladder carcinoma through pattern of interleukin-2 gene expression. J. Clin. Oncol., 14: 1778, 1996.
7. Kovach, J. S., Hartamnn, A., Blasyk, H., Cunningham, J., Schaid, D. and Sommer, S. S.: Mutation detection by highly sensitive methods indicates that p53 gene mutations in breast cancer can have important prognostic value. Proc. Natl. Acad. Sci., USA, 93: 1093, 1996.
8. Esrig, D., Elmajian, D., Groshen, S., Jones, P. A. and Cote, R. J.: Accumulation of nuclear p53 and tumor progression in bladder cancer. N. Engl. J. Med., 331: 1259, 1994.
9. Finlay, C. A., Hinds, P. W. and Levine, A. J.: The p53 protooncogene can act as a suppressor of transformation. Cell, 57: 1083, 1989.
10. Eliyahu, D., Michalovitz, D., Eliyahu, S., Pinhasi-Kimhi, O. and Oren, M.: Wild-type p53 can inhibit oncogene-mediated focus formation. Proc. Natl. Acad. Sci. USA, 86: 8763, 1989.
11. Oldstone, M. B., Tishon, A., Geckler, R., Lewicki, H. and Whitton, J. L.: A common anti-viral cytotoxic T-lymphocyte epitope for diverse major histocompatibility complex haplotypes: implications for vaccination. Proc. Natl. Acad. Sci. USA, 89: 2752, 1992.
12. Finlay, C. A., Hinds, P. W., Tan, T. H., Eliyahu, D., Oren, M. and Levine, A. J.: Activating mutations for transformation by p53 produce a gene product that forms an hsc70-p53 complex with altered half-life. Mol. Cell. Biol., 8: 531, 1988.
13. Vogelstein, B. and Kinzler, K. W.: p53 function and dysfunction. Cell, 70: 523, 1992.
14. Schlichtholz, B., Tredaniel, J., Lubin, R., Zalcman, G., Hirsch, A. and Soussi, T.: Analyses of p53 antibodies in sera of patients with lung carcinoma define immunodominant regions in the p53 protein. Br. J. Cancer, 69: 809, 1994.
15. Soussi, T.: The humoral response to the tumor-suppressor gene product p53 in human cancer: implications for diagnosis and therapy. Immunol. Today, 17: 354, 1996.
16. Shibata, Y., Kotanagi, H., Andoh, H., Koyama, K., Itoh, H. and Kudo, S.: Detection of circulating anti-p53 antibodies in patients with colorectal carcinoma and the antibody's relation to clinical factors. Dis. Colon Rectum, 39: 1269, 1996.
17. Yu, Z., Lui, X., McCart, T. M., Diamond, D. J. and Ellenhorn, J. D. I.: The use of transgenic mice to generate high affinity p53 specific cytolytic T cells. J. Surg. Res., 66: 337, 1997.
18. McCarty, T. M., Yu, Z., Lui, X., Diamond, D. J. and Ellenhorn, J. D. I.: An HLA Restricted, p53 specific immune response from HLA transgenic p53 knock-out mice. Ann. Surg. Oncol., 5: 93, 1997.
19. O'Toole, C., Price, Z. H. and Unsgaard, B.: Ultrastructure, karyology and immunology of a cell line originated from a human transitional cell carcinoma. Br. J. Cancer, 38: 64, 1978.
20. Kawasaki, T., Tomita, Y. and Sato, S.: mRNA and protein expression of p53 mutations in human bladder cancer cell lines. Cancer Lett., 82: 113, 1994.
21. Dubeau, L. and Jones, P. A.: Growth of normal and neoplastic urothelium and response to epidermal growth factor in a defined serum-free medium. Cancer Res., 47: 2107, 1987.
22. Salter, R. D. and Cresswell, P.: Impaired assembly and transport of HLA A and B antigens in a mutant TxB hybrid. EMBO J., 5: 943, 1986.
23. Fogh, J., Fogh, J. M. and Orfeo, T.: On hundred and twenty-seven cultured human tumor cell lines producing tumors in nude mice. J. Natl. Cancer Inst., 59: 221, 1977.
24. Diamond, D. J., York, J., Sun, J. Y., Wright, C. J. and Forman, S. J.: Development of a candidate HLA A*0201 restricted peptide-based vaccine against human cytomegalovirus infection. Blood, 90: 1751, 1997.
25. McCarty, T. M., Lui, X., Sun, J. Y., Peralta, E. A., Diamond, D. J. and Ellenhorn, J. D. I.: Targeting p53 for adoptive T cell immunotherapy. Cancer Res., 58: 2601, 1998.
26. Glick, S. H., Howell, L. P. and White, R. W. D.: Relationship of p53 and Bcl-2 to prognosis in Muscle-invasive transitional cell carcinoma of the bladder. J. Urol., 155: 1754, 1996.
27. Ahlering, T. E., Dubeau, L. and Jones, P. A.: A new in vivo model to study invasion and metastasis of human bladder carcinoma. Cancer Res., 47: 6660, 1987.
28. Guéguen, M., Patard, J., Gaugler, B., Brasseur, F., Renauld, J. C., Van Cangh, P. J., Boon, T. and Van den Eynde, B. J.: An antigen recognized by autologous CTLs on a human bladder carcinoma. J. Immunol., 160: 6188, 1998.
29. Spruck III, C. H., Ohnseit, P. F., Gonzalez-Zulueta, M., Esrig, D., Cote, R. J., Dubeau, L. and Jones, P. A.: Two molecular pathways to transitional cell carcinoma of the bladder. Cancer Res., 54: 784, 1994.
30. Brosman, S. A.: The influence of Tice strain BCG treatment in patients with transitional cell carcinoma in situ. In: BCG in Superficial Bladder Cancer. Edited by F. M. J. Debruyne, L. Denis and A. P. M. van der Meijden. New York, Alan R. Liss, p. 193, 1989.
31. Chang, F., Syrjanen, S. and Syrjanen, K.: Implications of the p53 tumor suppressor gene in clinical oncology. J. Clin. Oncol., 13: 1009, 1995.
32. Mayordomo, J. I., Loftus, D. J., Sakamoto, H., DeCesare, C. M., Appasamy, P. M., Lotze, M. T., Storkus, W. J., Appella, E. and DeLeo, A. B.: Therapy of murine tumors with p53 wild-type and mutant sequence peptide-based vaccines. J. Exp. Med., 183: 1357, 1996.
33. Roth, J., Dittmer, D., Rea, D., Tartaglia, J., Paoletti, E. and Levine, A. J.: p53 as a target for vaccines: tecombinant canary-pox virus expressing p53 protect mice against lethal tumor challenge. Proc. Natl. Acad. Sci. USA, 93: 4781, 1996.
34. Vierboom, M. P., Nijman, H. W., Offinga, R., van der Voort, E. I., van Hall, T., van den Broek, L., Jan Fleuren, G., Kenemans, P., Kast, W. M. and Melief, C. J.: Tumor eradication by wld-type p53-specific cytotoxic T lymphocytes. J. Exp. Med., 186: 695, 1997.
35. Houbiers, J. G., Nijman, H. W., van der Burg, S. H., Drijfhout, J. W., Kenemans, P., van de Velde, C. J., Brand, A., Momburg, F., Kast, W. M. and Melief, C. J.: In vitro induction of human cytotoxic T lymphocytes responses against peptides of mutant and wild-type p53. Eur. J. Immunol., 23: 2072, 1993.
36. Nijman, H. W., Houbiers, J. G., van der Burg, S. H., Vierboom, M. P., Kenemans, P., Kast, W. M. and Melief, C. J.: Characterization of cytotoxic T lymphocyte epitopes of a self-protein, p53, and a non-self protein, Influenza matrix: relationship between major histocompatibility complex peptide binding affinity and immune responsiveness to peptides. J. Immunother., 14: 121, 1993.
37. Nijman, H. W., van der Burg, S. H., Vierboom, M. P., Houbiers, J. G., Kast, W. M. and Melief, C. J.: p53, a potential target for tumor-directed T cells. Immunol. Lett., 40: 171, 1994.
38. Ropke, M., Hald, J., Guldberg, P., Zeuthen, J., Norgaard, L., Fugger, L., Svejgaard, A., van der Burg, S. H., Nijman, H. W., Melief, C. J. and Claesson, M. H.: Spontaneous human squamous cell carcinomas are killed by a human cytotoxic T lymphocyte clone recognizing a wild-type p53-derived peptide. Proc. Natl. Acad. Sci. USA, 93: 14704, 1996.